
Johnson & Johnson has reached an agreement to ship as many as 400 million doses of their COVID-19 vaccine to …

The European Commission has granted marketing authorisation to Roche and PTC Therapeutics’ Evrysdi, for the treatment of patients aged 2 …

Novartis has announced today that it has obtained exclusive rights to develop therapeutic applications for a library of fibroblast activation …

GSK has reached an agreement with Novavax and the UK Government Vaccines Taskforce to support the production of up to …

Incyte have received approval from the European Commission (EC) for Pemazyre (pemigatinib), the first new treatment for adults with locally …

More than 500,000 doses of Moderna’s COVID-19 vaccine are set to arrive in the UK next month, ministers have confirmed. …

GSK and Vir Biotechnology have submitted an Emergency Use Authorization request to the FDA for their VIR-7831 therapy for the …

Janssen’s PONVORY therapy for the treatment of adults with relapsing forms of multiple sclerosis (MS) has been recommended by the …

BATM have announced that it has developed a new method for the rapid and comprehensive diagnosis of tuberculosis (TB), which …

The UK’s National Institute for Health Research (NIHR) has awarded a £135,000 grant to gaitQ, a spin-off from the University …

In the last week, a number of new developments have made the news; for COVID-19, Starpharma will begin to sell …

The FDA have approved a new indication for Astellas Pharma’s Myrbetriq and Myrbetriq Granules to treat neurogenic detrusor overactivity (NDO), …

Astellas Pharma and Seagen Inc. have announced that the EMA has accepted their marketing authorisation application (MAA) for enfortumab vedotin, …

Novavax is delaying the signing of a contract to supply COVID-19 vaccines to the EU, as the company warned it …

Pfizer have begun testing its COVID-19 vaccine on children under the age of 12, with the trials’ first participants, a …

Australian biotech company, Starpharma, has announced a deal with LloydsPharmacy to sell its COVID-fighting antiviral nasal spray, Viraleze, in the …

Merck (MSD in the UK), the UCLA, and other universities from the US and Germany have uncovered a compound that …

AstraZeneca have revised their findings from the US study AZD1222 of their COVID-19 vaccine, announcing a 76% efficacy against symptoms …

MSD has announced a provisional agreement with the NHS to make KEYTRUDA (pembrolizumab) available for eligible patients with metastatic MSI-H/dMMR …

Both AstraZeneca and J&J face major manufacturing deficiencies for their recombinant vector COVID-19 vaccines, forcing competition over limited production capacity …